 Metronidazole
"Metronidazole" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A nitroimidazole used to treat AMEBIASIS; VAGINITIS; TRICHOMONAS INFECTIONS; GIARDIASIS; ANAEROBIC BACTERIA; and TREPONEMAL INFECTIONS. It has also been proposed as a radiation sensitizer for hypoxic cells. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985, p133), this substance may reasonably be anticipated to be a carcinogen (Merck, 11th ed).
| Descriptor ID |
D008795
|
| MeSH Number(s) |
D02.640.672.500 D03.383.129.308.658.500
|
| Concept/Terms |
Metronidazole- Metronidazole
- 2-Methyl-5-nitroimidazole-1-ethanol
- 2 Methyl 5 nitroimidazole 1 ethanol
Metronidazole Phosphate- Metronidazole Phosphate
- Phosphate, Metronidazole
- Metronidazole Phosphoester
- Phosphoester, Metronidazole
Metronidazole Hydrochloride- Metronidazole Hydrochloride
- Hydrochloride, Metronidazole
- Metronidazole Monohydrochloride
- Monohydrochloride, Metronidazole
|
Below are MeSH descriptors whose meaning is more general than "Metronidazole".
Below are MeSH descriptors whose meaning is more specific than "Metronidazole".
This graph shows the total number of publications written about "Metronidazole" by people in UAMS Profiles by year, and whether "Metronidazole" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2025 | 0 | 1 | 1 | | 2024 | 1 | 0 | 1 | | 2021 | 0 | 1 | 1 | | 2020 | 2 | 0 | 2 | | 2019 | 1 | 0 | 1 | | 2018 | 0 | 1 | 1 | | 2017 | 1 | 0 | 1 | | 2016 | 1 | 1 | 2 | | 2013 | 2 | 1 | 3 | | 2012 | 2 | 0 | 2 | | 2011 | 3 | 2 | 5 | | 2010 | 0 | 1 | 1 | | 2009 | 2 | 0 | 2 | | 2006 | 1 | 0 | 1 | | 2005 | 0 | 1 | 1 | | 2004 | 0 | 1 | 1 | | 2003 | 0 | 2 | 2 | | 2002 | 1 | 1 | 2 | | 2001 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Metronidazole" by people in Profiles over the past ten years.
-
Wu PJ, Tsay FW, Wu DC, Yang JC, Chuah SK, Chen KY, Chen CL, Lee CL, Shih CA, Liu YH, Shiu SI, Tai WC, Kuo CH, Lei WY, Kao SS, Tsai TJ, Feng IC, Koseki M, Hsu PI, Sheu MJ. Sequential changes of antibiotic resistances of Helicobacter pylori in Taiwan from 2019 to 2024. World J Gastroenterol. 2025 Oct 21; 31(39):111380.
-
Paulissen E, Martin BL. A Chemically Inducible Muscle Ablation System for the Zebrafish. Zebrafish. 2024 06; 21(3):243-249.
-
Hsu PI, Tsay FW, Kao JY, Peng NJ, Chen YH, Tang SY, Kuo CH, Kao SS, Wang HM, Wu IT, Shie CB, Chuah SK, Wu DC. Tetracycline-levofloxacin versus amoxicillin-levofloxacin quadruple therapies in the second-line treatment of Helicobacter pylori infection. Helicobacter. 2021 Oct; 26(5):e12840.
-
Schwebke JR, Lensing SY, Lee J, Muzny CA, Pontius A, Woznicki N, Aguin T, Sobel JD. Treatment of Male Sexual Partners of Women With Bacterial Vaginosis: A Randomized, Double-Blind, Placebo-Controlled Trial. Clin Infect Dis. 2021 08 02; 73(3):e672-e679.
-
Commander SJ, Gao J, Zinkhan EK, Heresi G, Courtney SE, Lavery AP, Delmore P, Sokol GM, Moya F, Benjamin D, Bumpass TG, Debski J, Erinjeri J, Sharma G, Tracy ET, Smith PB, Cohen-Wolkowiez M, Hornik CP. Safety of Metronidazole in Late Pre-term and Term Infants with Complicated Intra-abdominal Infections. Pediatr Infect Dis J. 2020 09; 39(9):e245-e248.
-
Chang YL, Tung YC, Tu YK, Yeh HZ, Yang JC, Hsu PI, Kim SE, Wu MF, Liou WS, Shiu SI. Efficacy of second-line regimens for Helicobacter pylori eradication treatment: a systemic review and network meta-analysis. BMJ Open Gastroenterol. 2020 09; 7(1).
-
Stancil SL, Pearce RE, Tyndale RF, Kearns GL, Vyhlidal CA, Leeder JS, Abdel-Rahman S. Evaluating metronidazole as a novel, safe CYP2A6 phenotyping probe in healthy adults. Br J Clin Pharmacol. 2019 05; 85(5):960-969.
-
Hsu PI, Pan CY, Kao JY, Tsay FW, Peng NJ, Kao SS, Wang HM, Tsai TJ, Wu DC, Chen CL, Tsai KW. Helicobacter pylori eradication with bismuth quadruple therapy leads to dysbiosis of gut microbiota with an increased relative abundance of Proteobacteria and decreased relative abundances of Bacteroidetes and Actinobacteria. Helicobacter. 2018 Aug; 23(4):e12498.
-
Njoku JC, Van Schooneveld TC, Rupp ME, Olsen KM, Qiu F, Meza JL, Hermsen ED. Lack of Benefit With Combination Therapy for Clostridium difficile Infection. Infect Control Hosp Epidemiol. 2017 05; 38(5):602-605.
-
Wang LA, Gonzalez D, Leeder JS, Tyndale RF, Pearce RE, Benjamin DK, Kearns GL, Cohen-Wolkowiez M. Metronidazole Metabolism in Neonates and the Interplay Between Ontogeny and Genetic Variation. J Clin Pharmacol. 2017 02; 57(2):230-234.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|